3-Amino-2-Bromo-5-Fluoropyridine | CAS:884495-03-8

We serve 3-Amino-2-Bromo-5-Fluoropyridine CAS:884495-03-8 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
3-Amino-2-Bromo-5-Fluoropyridine

Chemical Name: 3-Amino-2-Bromo-5-Fluoropyridine
CAS.NO:884495-03-8
Synonyms:2-bromo-5-fluoropyridin-3-amine;
Molecular Formula:C5H4BrFN2
Molecular Weight:191.00100
 
Physical and Chemical Properties:
Density:1.8±0.1 g/cm3
Melting point:114-116 °C
Boiling point:273.6±35.0 °C at 760 mmHg
Flash point:119.3±25.9 °C
Index of Refraction:1.65
 
Specification:
Appearance:colorless liquid
Purity:≥99.0%
 
Packing:25kg/drum
Storage:Store in a tightly closed container. Store in a cool, dry
Application:  used in the pharmaceutical intermediate



Contact us for information like 3-Amino-2-Bromo-5-Fluoropyridine chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,2-bromo-5-fluoropyridin-3-amine physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,3-Amino-2-Bromo-5-Fluoropyridine Use and application,3-Amino-2-Bromo-5-Fluoropyridine technical grade,usp/ep/jp grade.


Related News: Resonant exploits its proprietary IMPaCT tumor microenvironment models and data platform to discover novel, unappreciated targets and functionally active anti-tumor antibodies for difficult to treat tumors.2,3-Difluoro-4-propoxylphenylboronic acid manufacturer We purchase the raw materials from raw material or chemical product manufacturers both in Japan and internationally.2-Cyclopropyl-3-[(diphenylphosphinyl)methyl]-4-(4-fluorophenyl)quinolin supplier We purchase the raw materials from raw material or chemical product manufacturers both in Japan and internationally.(6-phenyldibenzo[b,d]furan-4-yl)boronic acid vendor It also said it would bar South Koreans from visiting China as tourists.In the early stage of market development, API companies usually need to strive to become a supply company for pharmaceutical companies after quickly completing product preparations. In the subsequent scale-up of production and market application, the relationship between pharmaceutical companies and API companies will become closer. The choice of R & D products of pharmaceutical companies will also be affected by pharmaceutical companies in turn.